Biotherapy of pancreatic neuroendocrine tumors using somatostatin analogs

Hisato Igarashi, Masayuki Hijioka, Lingaku Lee, Tetsuhide Ito

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Basically, pancreatic neuroendocrine tumor (PNET) should be treated surgically; however, in unresectable cases, a treatment that aims to improve the prognosis by inhibiting the growth of the tumor and control the clinical symptoms becomes necessary. In the case of functional tumors, the quality of life of patients is decreased by not only the symptoms with tumor invasion and/or metastasis but also by the symptoms of hormone excess. The efficacy of somatostatin analogs against the latter has been previously reported, and their sustained release formulations have been developed. Somatostatin analogs are recommended to treat the endocrine symptoms of functional PNET; however, in case they can cause hypoglycemia in patients with insulinoma. On the other hand, results from the PROMID study demonstrated a tumor-stabilizing effect when octreotide LAR (long acting repeatable) was used to treat patients with advanced midgut NET; however, there has been no consensus regarding its antitumor effect for PNET. Additionally, a recent result from the CLARINET study suggests that lanreotide autogel has an antitumor effect against nonfunctional NET including PNET. Further clinical study results are awaited.

Original languageEnglish
Pages (from-to)618-622
Number of pages5
JournalJournal of Hepato-Biliary-Pancreatic Sciences
Volume22
Issue number8
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Biological Therapy
Neuroendocrine Tumors
Somatostatin
Neoplasms
Insulinoma
Octreotide
Hypoglycemia
Quality of Life
Hormones
Neoplasm Metastasis
Growth
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hepatology

Cite this

Biotherapy of pancreatic neuroendocrine tumors using somatostatin analogs. / Igarashi, Hisato; Hijioka, Masayuki; Lee, Lingaku; Ito, Tetsuhide.

In: Journal of Hepato-Biliary-Pancreatic Sciences, Vol. 22, No. 8, 01.08.2015, p. 618-622.

Research output: Contribution to journalArticle

Igarashi, Hisato ; Hijioka, Masayuki ; Lee, Lingaku ; Ito, Tetsuhide. / Biotherapy of pancreatic neuroendocrine tumors using somatostatin analogs. In: Journal of Hepato-Biliary-Pancreatic Sciences. 2015 ; Vol. 22, No. 8. pp. 618-622.
@article{0d06c38fa73a4bca9c9099ac0c0b2a44,
title = "Biotherapy of pancreatic neuroendocrine tumors using somatostatin analogs",
abstract = "Basically, pancreatic neuroendocrine tumor (PNET) should be treated surgically; however, in unresectable cases, a treatment that aims to improve the prognosis by inhibiting the growth of the tumor and control the clinical symptoms becomes necessary. In the case of functional tumors, the quality of life of patients is decreased by not only the symptoms with tumor invasion and/or metastasis but also by the symptoms of hormone excess. The efficacy of somatostatin analogs against the latter has been previously reported, and their sustained release formulations have been developed. Somatostatin analogs are recommended to treat the endocrine symptoms of functional PNET; however, in case they can cause hypoglycemia in patients with insulinoma. On the other hand, results from the PROMID study demonstrated a tumor-stabilizing effect when octreotide LAR (long acting repeatable) was used to treat patients with advanced midgut NET; however, there has been no consensus regarding its antitumor effect for PNET. Additionally, a recent result from the CLARINET study suggests that lanreotide autogel has an antitumor effect against nonfunctional NET including PNET. Further clinical study results are awaited.",
author = "Hisato Igarashi and Masayuki Hijioka and Lingaku Lee and Tetsuhide Ito",
year = "2015",
month = "8",
day = "1",
doi = "10.1002/jhbp.227",
language = "English",
volume = "22",
pages = "618--622",
journal = "Journal of Hepato-Biliary-Pancreatic Sciences",
issn = "1868-6974",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Biotherapy of pancreatic neuroendocrine tumors using somatostatin analogs

AU - Igarashi, Hisato

AU - Hijioka, Masayuki

AU - Lee, Lingaku

AU - Ito, Tetsuhide

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Basically, pancreatic neuroendocrine tumor (PNET) should be treated surgically; however, in unresectable cases, a treatment that aims to improve the prognosis by inhibiting the growth of the tumor and control the clinical symptoms becomes necessary. In the case of functional tumors, the quality of life of patients is decreased by not only the symptoms with tumor invasion and/or metastasis but also by the symptoms of hormone excess. The efficacy of somatostatin analogs against the latter has been previously reported, and their sustained release formulations have been developed. Somatostatin analogs are recommended to treat the endocrine symptoms of functional PNET; however, in case they can cause hypoglycemia in patients with insulinoma. On the other hand, results from the PROMID study demonstrated a tumor-stabilizing effect when octreotide LAR (long acting repeatable) was used to treat patients with advanced midgut NET; however, there has been no consensus regarding its antitumor effect for PNET. Additionally, a recent result from the CLARINET study suggests that lanreotide autogel has an antitumor effect against nonfunctional NET including PNET. Further clinical study results are awaited.

AB - Basically, pancreatic neuroendocrine tumor (PNET) should be treated surgically; however, in unresectable cases, a treatment that aims to improve the prognosis by inhibiting the growth of the tumor and control the clinical symptoms becomes necessary. In the case of functional tumors, the quality of life of patients is decreased by not only the symptoms with tumor invasion and/or metastasis but also by the symptoms of hormone excess. The efficacy of somatostatin analogs against the latter has been previously reported, and their sustained release formulations have been developed. Somatostatin analogs are recommended to treat the endocrine symptoms of functional PNET; however, in case they can cause hypoglycemia in patients with insulinoma. On the other hand, results from the PROMID study demonstrated a tumor-stabilizing effect when octreotide LAR (long acting repeatable) was used to treat patients with advanced midgut NET; however, there has been no consensus regarding its antitumor effect for PNET. Additionally, a recent result from the CLARINET study suggests that lanreotide autogel has an antitumor effect against nonfunctional NET including PNET. Further clinical study results are awaited.

UR - http://www.scopus.com/inward/record.url?scp=84937514912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937514912&partnerID=8YFLogxK

U2 - 10.1002/jhbp.227

DO - 10.1002/jhbp.227

M3 - Article

C2 - 25689143

AN - SCOPUS:84937514912

VL - 22

SP - 618

EP - 622

JO - Journal of Hepato-Biliary-Pancreatic Sciences

JF - Journal of Hepato-Biliary-Pancreatic Sciences

SN - 1868-6974

IS - 8

ER -